SHAANXI KANGHUI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.94 CNY | +0.65% |
|
+10.90% | -25.73% |
| Apr. 26 | Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 15 | Kanghui Pharmaceutical to Earn 151 Million Yuan from Kelavi Buyback | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,541 | 1,720 | 1,676 | 2,174 | 1,773 | 1,875 |
| Enterprise Value (EV) 1 | 1,044 | 1,249 | 1,505 | 2,346 | 2,086 | 2,193 |
| P/E ratio | 27.6 x | 40 x | 49.4 x | 58.8 x | -28.2 x | -72.2 x |
| Yield | 0.73% | 0.5% | 0.42% | 0.34% | - | - |
| Capitalization / Revenue | 4.1 x | 3.99 x | 4.05 x | 4.91 x | 3.61 x | 2.79 x |
| EV / Revenue | 2.78 x | 2.9 x | 3.63 x | 5.3 x | 4.24 x | 3.26 x |
| EV / EBITDA | 16.6 x | 21.3 x | 32.6 x | 67.8 x | 122 x | 50.3 x |
| EV / FCF | 21.3 x | 4.25 x | -10.4 x | -9.87 x | -14.8 x | 27.4 x |
| FCF Yield | 4.69% | 23.5% | -9.6% | -10.1% | -6.77% | 3.65% |
| Price to Book | 1.63 x | 1.76 x | 1.66 x | 2.08 x | 1.82 x | 1.88 x |
| Nbr of stocks (in thousands) | 99,880 | 99,880 | 99,880 | 99,880 | 99,880 | 99,880 |
| Reference price 2 | 15.43 | 17.22 | 16.78 | 21.77 | 17.75 | 18.77 |
| Announcement Date | 4/26/19 | 4/22/20 | 4/22/21 | 4/28/22 | 4/28/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 375.6 | 431.4 | 414.1 | 442.8 | 491.5 | 673 |
| EBITDA 1 | 62.83 | 58.53 | 46.16 | 34.6 | 17.15 | 43.6 |
| EBIT 1 | 52.12 | 46.68 | 34.25 | 18.27 | -8.166 | 5.885 |
| Operating Margin | 13.88% | 10.82% | 8.27% | 4.13% | -1.66% | 0.87% |
| Earnings before Tax (EBT) 1 | 68.29 | 55.87 | 43.54 | 38.59 | -82.74 | -57.94 |
| Net income 1 | 55.63 | 42.76 | 34.11 | 36.48 | -63.06 | -26.16 |
| Net margin | 14.81% | 9.91% | 8.24% | 8.24% | -12.83% | -3.89% |
| EPS 2 | 0.5600 | 0.4300 | 0.3400 | 0.3700 | -0.6300 | -0.2600 |
| Free Cash Flow 1 | 48.96 | 293.7 | -144.4 | -237.7 | -141.3 | 79.99 |
| FCF margin | 13.04% | 68.08% | -34.88% | -53.68% | -28.74% | 11.89% |
| FCF Conversion (EBITDA) | 77.92% | 501.78% | - | - | - | 183.49% |
| FCF Conversion (Net income) | 88.02% | 686.8% | - | - | - | - |
| Dividend per Share 2 | 0.1130 | 0.0860 | 0.0700 | 0.0740 | - | - |
| Announcement Date | 4/26/19 | 4/22/20 | 4/22/21 | 4/28/22 | 4/28/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 172 | 313 | 318 |
| Net Cash position 1 | 497 | 471 | 171 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 4.97 x | 18.25 x | 7.304 x |
| Free Cash Flow 1 | 49 | 294 | -144 | -238 | -141 | 80 |
| ROE (net income / shareholders' equity) | 6.11% | 4.62% | 3.49% | 3.02% | -7.17% | -4.96% |
| ROA (Net income/ Total Assets) | 3.04% | 2.6% | 1.75% | 0.72% | -0.28% | 0.19% |
| Assets 1 | 1,829 | 1,642 | 1,946 | 5,067 | 22,747 | -13,775 |
| Book Value Per Share 2 | 9.480 | 9.790 | 10.10 | 10.50 | 9.750 | 9.990 |
| Cash Flow per Share 2 | 2.200 | 2.960 | 1.950 | 2.040 | 2.270 | 1.720 |
| Capex 1 | 5.58 | 81.4 | 266 | 290 | 138 | 72.4 |
| Capex / Sales | 1.49% | 18.88% | 64.14% | 65.57% | 28.1% | 10.76% |
| Announcement Date | 4/26/19 | 4/22/20 | 4/22/21 | 4/28/22 | 4/28/23 | 4/26/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -25.73% | 192M | |
| +20.61% | 43.18B | |
| +20.67% | 22.59B | |
| +14.56% | 14.56B | |
| +13.94% | 13.54B | |
| +43.35% | 11.5B | |
| -8.37% | 6.93B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.36B |
- Stock Market
- Equities
- 603139 Stock
- Financials Shaanxi Kanghui Pharmaceutical Co., Ltd.
